Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial - 15/07/23
Doi : 10.1016/j.jaad.2023.02.061
Takemichi Fukasawa, MD a, Ayumi Yoshizaki, MD a, ⁎ 
, Satoshi Ebata, MD a, Maiko Fukayama, MD a, Ai Kuzumi, MD a, Yuta Norimatsu, MD a, Kazuki M. Matsuda, MD a, Hirohito Kotani, MD a, Hayakazu Sumida, MD a, Asako Yoshizaki-Ogawa, MD a, Hisashi Kagebayashi, MSc b, Shinichi Sato, MD a, ⁎
, Satoshi Ebata, MD a, Maiko Fukayama, MD a, Ai Kuzumi, MD a, Yuta Norimatsu, MD a, Kazuki M. Matsuda, MD a, Hirohito Kotani, MD a, Hayakazu Sumida, MD a, Asako Yoshizaki-Ogawa, MD a, Hisashi Kagebayashi, MSc b, Shinichi Sato, MD a, ⁎ a Department of Dermatology, The University of Tokyo, Graduate School of Medicine, Tokyo, Japan
b Kyowa Kirin Co, Ltd, Tokyo, Japan
∗Correspondence and reprint requests to: Ayumi Yoshizaki, MD, Department of Dermatology, The University of Tokyo, Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, JapanDepartment of DermatologyThe University of TokyoGraduate School of Medicine7-3-1 Hongo, Bunkyo-kuTokyo113-8655Japan∗∗Shinichi Sato, MD, Department of Dermatology, The University of Tokyo, Graduate School of Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, JapanDepartment of DermatologyThe University of TokyoGraduate School of Medicine7-3-1 Hongo, Bunkyo-kuTokyo113-8655Japan
Key words : brodalumab, fibrosis, interleukin-17, interleukin-17 receptor, Japan, phase 1, systemic sclerosis
| Drs Fukasawa and Yoshizaki contributed equally to this study. |
|
| Funding sources: Funding for this study was provided by Kyowa Kirin Co, Ltd, Japan. |
|
| IRB approval status: This study was conducted in accordance with the Declaration of Helsinki and the guidelines for Good Clinical Practice (Clinicaltrials.gov listing: NCT04368403) and approved by the Institutional Review Board of the University of Tokyo Hospital (approval number:2017009-11X). |
|
| Patient consent: All patients provided written informed consent. |
© 2023
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 89 - N° 2
P. 366-369 - août 2023 Retour au numéro
Article précédent
- Cutaneous neonatal lupus in patients with skin of color: A retrospective cohort study from a national registry
- Julianne Kleitsch, Daniel R. Mazori, Mala Masson, Peter M. Izmirly, Amit Saxena, Jill P. Buyon, Sharon A. Glick
- Incidence trends of melanoma among young adults: An epidemiologic study in Olmsted County, Minnesota
- Olivia M. Crum, Elliott H. Campbell, Jacob P. Reinhart, Sydney L. Proffer, Amy L. Weaver, Lawrence E. Gibson, Jerry D. Brewer, Addison M. Demer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?